Zacks Investment Research
17 Mar 2026, 14:41 UTC · 33w ago
Impact · against what's priced in
ACXP shows strong fundamental momentum with a 42.5% increase in full-year earnings estimates and a #2 Zacks Rank. APYX also demonstrates improving sentiment with a 17.1% EPS estimate increase, though ACXP's growth trajectory is more aggressive.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Acurx Pharmaceuticals (ACXP) has seen its full-year earnings consensus estimate increase by 42.5% over the past quarter.
More positive than 93% of claims this week
Acurx Pharmaceuticals (ACXP) is currently assigned a Zacks Rank of #2 (Buy).
So whatA high quantitative rank suggesting potential market outperformance over the next 1-3 months serves as a positive signal for investors.
Continue reading
5 related stories
Full-year earnings consensus estimates have increased by 42.5% over the last quarter, and the stock currently holds a Zacks Rank of #2.
Read from the article alone
No priced-in read yet
Consensus EPS estimates for the current year have risen by 17.1% over the last three months.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
Apyx Medical (APYX) has seen its consensus EPS estimate for the current year increase by 17.1% over the last three months.
More positive than 62% of claims this week
The Medical sector currently holds a Zacks Sector Rank of #10 out of 16, indicating relative underperformance compared to other sectors.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), significant earnings estimate increases, and has outperformed its sector with 93.2% YTD returns.
More positive than 75% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), an increase in consensus EPS estimates, and has outperformed its sector YTD.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
53m ago
−20.1%
Price is moving against the score
$2.93 vs $3.67 close before publication (Mar 16) · not market-adjusted
APYX chart →−77.1%
Price is moving against the score
$1.10 vs $4.81 close before publication (Mar 16) · not market-adjusted
ACXP chart →
